---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-21-025178"
form_type: "8-K"
ticker: "MLAB"
cik: "0000724004"
company_name: "MESA LABORATORIES INC /CO/"
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T13:27:02.633034+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Mesa Labs Q2 FY22 revenue $35.84M (+12%), net income up 39% to $3.72M

## Summary
- Revenue $35.84M (+12% YoY); operating income $4.20M (-6%); net income $3.72M (+39%); diluted EPS $0.70 vs $0.51.
- Sterilization & Disinfection Control organic growth 21%; Biopharma Development organic growth 16%; Continuous Monitoring revenue record (+18%).
- Instrument division revenue down 8% due to component supply and labor constraints; backlog increased.
- Non-GAAP adjusted operating income $9.997M (flat YoY); adjusted diluted EPS $1.87 vs $1.91.
- Completed acquisition of Agena Bioscience on Oct 20, 2021, adding Clinical Genomics capabilities.

## SEC filing metadata
- accession: 0001437749-21-025178
- form_type: 8-K
- ticker: MLAB
- cik: 0000724004
- company_name: MESA LABORATORIES INC /CO/
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/724004/000143774921025178/0001437749-21-025178-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/724004/000143774921025178/mlab20211103_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-21-025178
- JSON: https://secwatch.observer/filing/0001437749-21-025178.json
- Plain text: https://secwatch.observer/filing/0001437749-21-025178.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.